Background And Aims: Over the last decade, treatment options for moderate-to-severe ulcerative colitis (UC) have expanded. However, comparative studies between these agents are limited, especially among biologic-naïve patients. We aimed to compare the persistence, effectiveness and safety of tofacitinib and vedolizumab as the first advanced treatment for patients with UC.
View Article and Find Full Text PDFA consequence of QCD axion dark matter being born after inflation is the emergence of small-scale substructures known as miniclusters. Although miniclusters merge to form minihalos, this intrinsic granularity is expected to remain imprinted on small scales in our galaxy, leading to potentially damaging consequences for the campaign to detect axions directly on Earth. This picture, however, is modified when one takes into account the fact that encounters with stars will tidally strip mass from the miniclusters, creating pc-long tidal streams that act to refill the dark matter distribution.
View Article and Find Full Text PDFBackground: Long-term vedolizumab (VDZ) outcomes in real-world cohorts have been largely limited to 1-year follow-up, with few bio-naïve patients or objective markers of inflammation assessed.
Objectives: We aimed to assess factors affecting VDZ persistence including clinical, biochemical and faecal biomarker remission at 1, 3 and 5 years.
Design: We performed a retrospective, observational, cohort study.